[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"Sri Lanka\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":591},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,48,78,112,148,176,198,223,250,278,304,334,362,389,423,453,480,502,538,565],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100636742","hfref-polypill-in-sri-lanka-rct-100636742",false,"NCT07569640","HFrEF Polypill in Sri Lanka RCT","Heart Failure With Reduced Ejection Fraction Polypill in Sri Lanka: A Multi-Center Type I Hybrid Randomized Controlled Trial","Inclusion Criteria:\n\n1. Adults (≥18 years old)\n2. Diagnosis of heart failure with reduced ejection fraction (HFrEF) including clinical symptoms or clinical signs or natriuretic peptide elevation AND echocardiographic or other evidence of reduced left ventricular ejection fraction (EF ≤40%)\n3. New York Heart Association Class II, III, or IV symptoms\n\nExclusion Criteria:\n\n1. Known contraindication to any of the HFrEF polypill components (e.g., advanced renal disease, bradycardia, allergy, amongst others).\n2. Significant renal impairment (estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73 m2).\n3. Raised serum potassium \\>5 mEq\u002FL.\n4. Symptomatic hypotension or systolic BP \\\u003C100 mmHg as per the average of last 2 of the 3 measurements at visit 1.\n5. Symptomatic bradycardia or second or third-degree heart block without a pacemaker on ECG review at visit 1.\n6. History of type 1 diabetes mellitus.\n7. Women who are pregnant, breastfeeding or of childbearing potential and are not using and do not plan to continue using a highly acceptable form of contraception throughout the study (pharmacological or barrier methods).\n8. Concomitant illness, physical impairment or mental condition which in the opinion of the study team\u002F primary physician could interfere with the conduct of the study including outcome assessment.\n9. Participation in a concurrent interventional medical investigation or pharmacologic clinical trial. Patients in observational, natural history or epidemiological studies not involving an intervention are eligible.\n10. Participant's responsible physician believes it is not appropriate for participant to participate in the study.\n11. Inability or unwillingness to provide written informed consent.\n12. Involvement in the planning and\u002For conduct of the study.\n13. Unable to complete study procedures and\u002For plan to move out of the study site area in the next 12 months.","ALL","18 Years",{"count":19,"type":20},1672,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The aim of this study is to evaluate, in adults with HFrEF in Sri Lanka, the effects of an HFrEF polypill implementation strategy on the composite rate of cardiovascular disease mortality and recurrent heart failure hospitalizations, compared with usual care over a minimum of 12-months of follow-up.\n\nPrimary outcome of the study:\n\n1\\) Composite rate of cardiovascular disease mortality and recurrent heart failure hospitalizations over study duration\n\nSecondary outcomes of the study:\n\n1. Rate of cardiovascular disease mortality over study duration\n2. Rate of recurrent heart failure hospitalizations over the study duration\n3. Rate of all-cause mortality over the study duration\n4. Change in left ventricular ejection fraction at 12-months and end of study assessed by transthoracic echocardiogram\n5. Change in BNP levels at 12 months and end of study\n6. Change in overall and domain specific health-related quality of life at 12-months and end of study assessed by a translated validated version of the Kansas City Cardiomyopathy Questionnaire (KCCQ-23)\n7. Change in physician-reported New York Heart Association class at 12-months and end of study\n8. Adherence to guideline-directed medical therapy assessed by pill count and MARS-5 questionnaire at baseline, 1-, 6-, 12-months, and end of study. Persistence assessed as continuation of assigned therapy at each follow-up visit. Dose optimization assessed as proportion achieving target doses (Strength 3 of the polypill, or comparable individual GDMT doses in the comparator arm) at 6-, 12-months, and end of study.\n\nSafety outcomes:\n\n1. Proportion of participants with serious adverse events according to Good Clinical Practice guidelines over study duration\n2. Proportion of participants with adverse events of special interest over study duration\n3. Proportion of participants with adverse events leading to HF drug discontinuation over study duration\n4. Mean change from baseline to 12-months and end of study in serum potassium (mEq\u002FL)\n5. Mean change from baseline to 12-months and end of study in serum creatinine (mg\u002FdL)\n\nParticipants will be randomly assigned 1:1 stratified by sex and site to one of two groups, intervention (experimental arm) or usual care (control arm). The intervention group will be given four guideline-recommended medications for heart failure with reduced ejection fraction, combined in one over-encapsulated pill, with three dose strength options. Both groups will be observed over a minimum of 12-months of follow-up to assess key outcomes.",[26],"Heart Failure With Reduced Ejection Fraction",[28,29,30,31,32,33,34],"HFrEF","Heart Failure","Heart Failure with Reduced Ejection Fraction","South Asia","Sri Lanka","Polypill","type I hybrid-effectiveness","RECRUITING","2026-08-21",{"date":38,"type":39},"2026-08-25","ACTUAL",{"date":41,"type":39},"2026-08-17",{"date":43,"type":20},"2029-04",{"name":45,"class":46},"Washington University School of Medicine","OTHER",10,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100653200","a-combination-triple-pill-implementation-strategy-for-blood-pressure-control-100653200","NCT07784647","A Combination Triple Pill Implementation Strategy for Blood Pressure cONtrol","A Low-Cost, Scalable Treatment Strategy for Improving Hypertension Control in Low and Middle-Income Settings: Formative Phase (Aim 1)","ACTION","SARA Facility Survey Inclusion Criteria:\n\n\\- primary care facility must be located in the Federal Capital Territory in Nigeria, and in the Gampaha District in Sri Lanka\n\nPatient Cross-Sectional Survey Inclusion Criteria:\n\n* adult (age ≥18 years)\n* hypertensive (defined as prior documented diagnosis of hypertension, or current use of BP-lowering drugs for hypertension, or SBP ≥140 mmHg, and\u002For DBP ≥90 mmHg measured on two separate occasions)\n\nPatient Cross-Sectional Survey Exclusion Criteria:\n\n* receiving BP-lowering drugs for conditions other than hypertension (e.g., benign prostate hyperplasia, migraine, etc)\n* normotensive",true,{"count":58,"type":20},1357,"OBSERVATIONAL","This study includes a survey of primary healthcare facilities in Nigeria and Sri Lanka. It will aim to assess the availability and readiness of hypertension care in primary healthcare facilities, and feasibility to conduct a future randomised controlled trial.\n\nThis study also includes a survey of patients with high blood pressure who will be recruited from primary care in Sri Lanka and Nigeria. Its aim is to understand the characteristics of patients with hypertension, hypertension management and control, including use of pharmacological interventions and lifestyle management. Patients will have their blood pressure, height and weight measured. They will also be asked about their age, sex\u002Fgender, socio-economic status, medical history, and health behaviours and lifestyle.\n\nAdditionally, this study includes focus group discussions and in-depth interviews with adults with high blood pressure and their carers; healthcare providers (community health workers, nurses, and doctors or physicians); clinic administrators; and policymakers. The discussions and interviews will aim to explore experiences, practices, and views on hypertension care and the new treatment strategies. Topics will cover experiences of current high blood pressure care; service availability, accessibility, and affordability; healthcare staff training and how well they follow medical guidelines for helping patients with high blood pressure; what works well and what are the problems with helping patients with high blood pressure; experiences of patients who need help with their high blood pressure; and how well new ways of helping people with high blood pressure are received.",[62,63],"Hypertension","Health Services Accessibility",[65,66,67,68],"service availability and readiness assessment","hypertension","health services accessibility","blood pressure","2026-08-20",{"date":38,"type":39},{"date":72,"type":39},"2026-04-01",{"date":74,"type":20},"2026-08-31",{"name":76,"class":46},"Imperial College London",2,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":86,"targetDuration":88,"studyType":59,"phases":4,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100651900","skin-type-determination-using-image-artificial-intelligence-100651900","NCT07765303","Skin Type Determination Using Image Artificial Intelligence","Skin Pigment Type, Phototype and Photodamage Determination Using Image Analyses Powered by Artificial Intelligence - SPAI Study","SPAI","Inclusion Criteria:\n\n* Aged 18 years or older\n* Able and willing to provide informed consent (oral or written, according to local regulations)\n* Willing to complete the study questionnaire\n* Willing to undergo non-invasive skin imaging and skin characteristic assessments of predefined sites on the upper arm and forearm\n\nExclusion Criteria:\n\n* Younger than 18 years of age\n* Unable to provide informed consent\n* Unable to complete study procedures\n* Tattoos, prominent scars, wounds, skin lesions, dressings, or other identifiable features at the predefined imaging sites that may interfere with image acquisition, assessment quality, or participant anonymity",{"count":87,"type":20},1500,"1 Day","Skin color, how easily a person burns or tans in the sun (skin phototype), and the amount of chronic sun damage in the skin are important factors in skin health. These characteristics influence a person's risk of skin cancer, how skin diseases appear, how well treatments work, and how accurately doctors and artificial intelligence (AI) systems can diagnose skin conditions. However, current methods for classifying these characteristics are often imprecise and rely heavily on subjective assessments. As a result, both healthcare professionals and patients may incorrectly classify skin type, which can lead to inaccurate risk assessments and less personalized care.\n\nThis study aims to develop and validate AI algorithms that can accurately classify skin pigmentation, skin phototype, and accumulated sun damage using photographs of the skin. Unlike existing approaches, the study combines several different methods to create a more objective \"ground truth\" for training the AI. These methods include skin color measurements using spectrophotometry or colorimetry, assessments using the Monk Skin Tone Scale, questionnaires about sun sensitivity, and clinical evaluations by trained observers. By combining these data sources, the researchers hope to create a more reliable and scientifically robust classification system.\n\nThe study will recruit adults aged 18 years and older from several countries, including countries from all continents. Participants will complete a questionnaire about their skin, propensity to burn and sun exposure history. Researchers will then take standardized close-up and dermoscopic images of the skin on the arm and forearm, measure skin pigmentation using objective instruments when available, and assess skin phototype and sun damage. No invasive procedures will be performed, and no personally identifiable information will be collected.\n\nThe collected images and measurements will be used to train deep learning AI models. The researchers aim to develop algorithms that can classify skin pigmentation with at least 85% accuracy, skin phototype with at least 75% accuracy, and sun damage with at least 80% accuracy compared with the combined reference assessments. The algorithms will then be tested in independent datasets, including large dermatology image databases from Sweden, to evaluate how well they perform in different populations.\n\nThe study has several potential benefits. More accurate classification of skin characteristics could improve personalized skin cancer risk assessments and allow prevention advice to be tailored to individual needs. This may help identify people who would benefit from closer surveillance and stronger sun protection recommendations while avoiding unnecessary restrictions for people at lower risk. Improved classification could also enhance the diagnosis and management of inflammatory skin diseases and skin cancers, which can appear differently in people with different skin tones.\n\nAn additional goal is to address known biases in dermatology AI systems, which often perform less accurately in individuals with darker skin. By including participants with a wide range of skin tones and backgrounds, the researchers aim to contribute to the benchmarking of AI-driven medical devices wich hopefully can result in the development of fairer and more equitable AI tools.\n\nThe study involves minimal risk. Only photographs of the arm and forearm will be taken, and researchers will avoid capturing tattoos, prominent scars, or other identifying features. All data will be stored securely and only accessible to authorized researchers. The potential benefits of improving skin disease diagnosis, skin cancer prevention, and fairness in medical AI are considered to outweigh the small privacy risks associated with participation.",[91,92],"Skin Ageing","Skin",[94,95,96,97,98,99,100,101],"skin tone","pigmentation","skin color","chronic sun damage","photodamage","sun sensitivity","phototype","Fitzpatrick type","2026-08-10",{"date":104,"type":39},"2026-08-14",{"date":106,"type":39},"2025-04-28",{"date":108,"type":20},"2028-12-31",{"name":110,"class":46},"Region Skane",11,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":21,"phases":122,"briefSummary":124,"conditions":125,"keywords":131,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":147},"100551903","phase-2-study-of-wal0921-in-patients-with-glomerular-kidney-diseases-100551903","NCT06466135","Study of WAL0921 in Patients With Glomerular Kidney Diseases","Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of WAL0921 in Patients With Glomerular Kidney Diseases and Proteinuria","Inclusion Criteria:\n\n* Adults, age 18-75 years\n* Diagnosis of one of the following glomerular kidney diseases: diabetic nephropathy; primary focal segmental glomerulosclerosis; treatment resistant-minimal change disease; primary IgA nephropathy; primary membranous nephropathy\n* eGFR greater than or equal to 30 mL\u002Fmin\u002F1.73 m2\n\nExclusion Criteria:\n\n* Currently pregnant or planning to become pregnant\n* History of organ transplantation\n* History of alcohol or substance use disorder\n* Acute dialysis or acute kidney injury within 6 months of Screening\n* Any prior or current medical condition that, in the judgment of the Investigator, would prevent the subject from safely participating in and\u002For completing all study requirements","75 Years",{"count":121,"type":20},96,[123],"PHASE2","This is an adaptive prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of WAL0921 in subjects with glomerular kidney disease and proteinuria, including diabetic nephropathy and rare glomerular kidney diseases (primary focal segmental glomerulosclerosis \\[FSGS\\], treatment-resistant minimal change disease \\[TR MCD\\], primary immunoglobulin A nephropathy \\[IgAN\\], and primary membranous nephropathy \\[PMN\\]). Subjects in this study will be randomized to receive the investigational drug WAL0921 or placebo as an intravenous infusion once every 2 weeks for 7 total infusions. All subjects will be followed for 24 weeks after their last infusion.",[126,127,128,129,130],"Diabetic Nephropathies","Primary Focal Segmental Glomerulosclerosis","Minimal Change Disease","Primary Immunoglobulin A Nephropathy","Primary Membranous Nephropathy",[132,133,134,135,136],"DN","FSGS","TR-MCD","IgAN","PMN","2026-07-30",{"date":139,"type":39},"2026-08-03",{"date":141,"type":39},"2024-07-02",{"date":143,"type":20},"2027-06",{"name":145,"class":146},"Walden Biosciences","INDUSTRY",50,{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":156,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":21,"phases":159,"briefSummary":161,"conditions":162,"keywords":164,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":175},"100541553","treatment-of-lower-respiratory-tract-infection-in-selected-hospitals-in-southern-sri-lanka-treat-sl-a-stepped-wedge-cluster-randomized-trial-100541553","NCT06331364","TREATment of Lower Respiratory Tract Infection in Selected Hospitals in Southern Sri Lanka (TREAT-SL): a Stepped-Wedge Cluster Randomized Trial","TREATment of Lower Respiratory Tract Infection in Selected Hospitals in Southern Sri Lanka (TREAT-SL): A Stepped-wedge Cluster Randomized Trial of an Electronic Clinical Decision Support Tool (eCDST) for the Diagnosis and Treatment of Lower Respiratory Tract Infection (LRTI) in Selected Hospitals in Southern Sri Lanka","TREAT-SL","Inclusion Criteria:\n\n1. Admitted within prior 48 hours\n2. Have evidence of new acute respiratory illness (\\\u003C14 days of symptoms), as indicated by at least one of the following:\n\n   1. New cough or sputum production\n   2. Chest pain\n   3. Dyspnea or tachypnea (respiratory rate \\>20 breaths\u002Fminute)\n   4. Abnormal lung examination\n3. Have evidence of acute infection, as indicated by at least one of the following:\n\n   1. Self-reported fever or chills\n   2. Documented fever ≥38 ̊ C (100.4 ̊ F)\n   3. Documented hypothermia \\\u003C35.5 ̊ C (95.9 ̊ F)\n   4. Leukocytosis (white blood cell count \\>10,000\u002Fmm3)\n   5. Leukopenia (white blood cell count \\\u003C3000\u002Fmm3)\n   6. New altered mental status\n4. Ability and willingness of patient, parent or legally authorized representative (LAR) to give informed consent\n5. Ability of children 14-17 years of age to provide assent\n6. Ability to complete follow-up encounter at 30 days in person or by telephone\n\nExclusion Criteria:\n\n1. Hospitalized recently (within last 28 days)\n2. If they have been enrolled into this clinical trial previously\n3. Surgery in the past 7 days\n4. If they are unable or unwilling to complete the follow-up encounter\n5. If they will likely be transferred from the medical wards within 24 hours of enrollment (to another ward or to another hospital)\n6. If they have underlying conditions or circumstances for which physicians would be unlikely to withhold antibacterials:\n\n   1. Vasopressor therapy\n   2. Cystic fibrosis\n   3. Known severe immunosuppression (i. Cancer or another condition with neutropenia (absolute neutrophil count \\\u003C1000\u002F microL; ii. Solid- organ or hematopoietic stem-cell transplant within the previous 90 days; iii. Active graft-versus-host disease or bronchiolitis obliterans; iv. On chronic steroids equivalent to prednisone 20mg daily for ≥ 2 weeks or other targeted cytotoxic or biologic immunosuppressants within the prior 4 weeks; v. Human immunodeficiency virus infection with a CD4 cell count \\\u003C200\u002Fmm3)\n   4. Have an accompanying non-respiratory infection\n   5. Have evidence of a lung abscess or empyema\n   6. Have respiratory failure at enrollment, evidenced by use of non-invasive or invasive ventilation","14 Years",{"count":158,"type":20},765,[160],"NA","This is a stepped-wedge, cluster-randomized, two-arm, open-label, clinical trial of an electronic clinical decision support tool (eCDST) for the diagnosis and treatment of lower respiratory tract infection (LRTI) among patients at three sites in Southern Province, Sri Lanka.\n\nThe primary objective of this trial is to determine the impact of an electronic clinical decision support tool (eCDST) on clinical outcomes and antibacterial prescription in subjects with LRTI in the intervention group compared to the control group.\n\nThe study will enroll 765 patients ≥ 14 years of age. Medical wards will be randomized in clusters to the intervention at intervals of 3-6 months until all clusters cross over. Participants will be followed for 30 days from enrollment to record clinical outcomes and any antimicrobials prescribed (a maximum of 14 days).",[163],"Lower Resp Tract Infection",[165],"eCDST","2026-07-22",{"date":168,"type":39},"2026-07-23",{"date":170,"type":39},"2026-02-27",{"date":172,"type":20},"2027-07-31",{"name":174,"class":46},"Duke University",3,{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":21,"phases":185,"briefSummary":186,"conditions":187,"keywords":188,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":190,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":197},"100517992","phase-3-a-study-to-determine-the-efficacy-and-safety-of-finerenone-and-sglt2i-in-combination-in-hospitalized-patients-with-heart-failure-confirmation-hf-100517992","NCT06024746","A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)","Combined Efficacy and Safety of an Early, Intensive, Management Strategy With Finerenone and SGLT2 Inhibitor in Patients Hospitalized With Heart Failure (CONFIRMATION-HF)","CONFIRMATION","Inclusion Criteria:\n\n* Provide electronic or written informed consent, either personally or through a legally authorized representative, as permitted by local regulations\n* Age ≥18 years or legal age of majority if \\>18 years in the participant's country of residence\n* Current hospitalization or recently discharged with the primary diagnosis of heart failure\n* Heart failure signs and symptoms at the time of hospital admission\n* Elevated N-terminal pro B-type natriuretic peptide (NTproBNP) ≥500 pg\u002FmL or B-type natriuretic peptide (BNP) ≥125 pg\u002FmL according to the local lab for patients in sinus rhythm; or elevated NTproBNP ≥1500 pg\u002FmL or BNP ≥375 pg\u002FmL for patients with atrial fibrillation (AF), measured during the current hospitalization or in the 72 hours prior to hospital admission\n* Fulfillment of protocol defined stabilization criteria (if randomized during hospitalization)\n* Treatment during the index hospitalization with at least 1 intravenous dose of a loop diuretic (e.g., furosemide, torsemide, bumetanide).\n* Negative pregnancy test and agreement to use adequate contraception during trial (female participants only)\n\nExclusion Criteria:\n\n* Diagnosis of type 1 diabetes or prior history of diabetic ketoacidosis\n* Documented prior history of severe hyperkalemia in the setting of MRA use\n* Treatment with non-steroidal mineralocorticoid receptor antagonist (MRA) or SGLT2i\n* Estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73m² and\u002For potassium \\>5.0 mmol\u002FL\n* Acute myocardial infarction, coronary revascularization, valve replacement\u002Frepair, or implantation of a cardiac resynchronization therapy device within 30 days\n* Prior or planned heart transplant\n* Hemodynamically significant uncorrected primary cardiac valvular disease as primary cause of heart failure\n* Cardiomyopathy due to acute inflammatory heart disease, infiltrative diseases, accumulation diseases, muscular dystrophies, cardiomyopathy with reversible causes, known hypertrophic obstructive cardiomyopathy, complex congenital heart disease, or pericardial constriction\n* Probable alternative cause of participant's heart failure symptoms\n* Concomitant systemic therapy with potent cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitors or moderate CYP3A4 inducers, or potent CYP3A4 inducers\n* Known hypersensitivity to the IP (active substance or excipients)\n* Any other condition or therapy which would make the patient unsuitable for this study",{"count":87,"type":20},[23],"Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.",[29],[29,189],"Hospitalized",{"date":168,"type":39},{"date":192,"type":39},"2024-07-09",{"date":194,"type":20},"2027-11",{"name":196,"class":46},"Colorado Prevention Center",104,{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":21,"phases":208,"briefSummary":209,"conditions":210,"keywords":211,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":222},"100518700","phase-3-a-study-to-evaluate-finerenone-on-clinical-efficacy-and-safety-in-patients-with-heart-failure-who-are-intolerant-or-not-eligible-for-treatment-with-steroidal-mineralocorticoid-receptor-antagonists-100518700","NCT06033950","A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists","A Randomized, Double-blind, Placebo-controlled Pragmatic Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure and Reduced Ejection Fraction Who Are Intolerant of or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists (FINALITY-HF)","FINALITY-HF","Inclusion Criteria:\n\n* Provide electronic or written informed consent, either personally or through a legally authorized representative, as permitted by local regulations\n* Age ≥18 years or legal age of majority if \\>18 years in the participant's country of residence\n* Symptomatic HFrEF per protocol defined criteria\n* Not on sMRA due to history of intolerance, contraindication, or ineligibility for treatment\n* Negative pregnancy test and agreement to use adequate contraception during trial (female participants only)\n\nExclusion Criteria:\n\n* Treatment with non-steroidal MRA (nsMRA)\n* Documented prior history of severe hyperkalemia in the setting of MRA use\n* eGFR \\\u003C 25 mL\u002Fmin\u002F1.73m² and \u002F or potassium \\> 5.0 mmol\u002FL\n* Acute myocardial infarction, coronary revascularization, valve replacement\u002Frepair, or implantation of a cardiac resynchronization therapy device within 30 days or planned\n* Prior or planned heart transplant\n* Hemodynamically significant (severe) uncorrected primary cardiac valvular disease considered by the investigator to be the primary cause of heart failure\n* Symptomatic bradycardia or second- or third-degree heart block without a pacemaker\n* Cardiomyopathy due to known acute inflammatory heart disease, infiltrative diseases, accumulation diseases, muscular dystrophies, cardiomyopathy with reversible causes, hypertrophic obstructive cardiomyopathy, complex congenital heart disease, or pericardial constriction\n* Probable alternative cause of participant's HF\n* Concomitant systemic therapy with potent cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitors, or moderate or potent CYP3A4 inducers\n* Known hypersensitivity to the IP (active substance or excipients)\n* Any other condition or therapy which would make the participant unsuitable for the study\n* Concurrent or previous participation in another interventional clinical study using an investigational agent within 30 days prior to randomization",{"count":207,"type":20},2600,[23],"Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients with heart failure and reduced ejection fraction (HFrEF) who are intolerant or ineligible to receive treatment with steroidal mineralocorticoid receptor antagonists (sMRA).",[29],[212,213],"Reduced ejection fraction","Symptomatic heart failure","2026-07-08",{"date":216,"type":39},"2026-07-10",{"date":218,"type":39},"2024-08-20",{"date":220,"type":20},"2028-01",{"name":196,"class":46},176,{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":21,"phases":233,"briefSummary":234,"conditions":235,"keywords":237,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":249},"100516720","phase-3-a-study-to-determine-the-efficacy-and-safety-of-finerenone-on-morbidity-and-mortality-among-hospitalized-heart-failure-patients-100516720","NCT06008197","A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients","Randomized Trial to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Heart Failure Patients With Left Ventricular Ejection Fraction Greater Than or Equal to 40% Hospitalized Due to an Episode of Acute Decompensated Heart Failure (REDEFINE-HF)","REDEFINE-HF","Inclusion Criteria:\n\n* Provide written informed consent\n* Age ≥18 years or legal age of majority if \\>18 years in the participant's country of residence\n* Current hospitalization or recently discharged (during or within 30 days of discharge) with the primary diagnosis of heart failure\n* Heart failure signs and symptoms at the time of hospital admission\n* Imaging evidence of mildly reduced or preserved left ventricular ejection fraction (EF) (40% or higher)\n* Elevated N-terminal pro B-type natriuretic peptide (NTproBNP) ≥500 pg\u002FmL or B-type natriuretic peptide (BNP) ≥125 pg\u002FmL for patients without atrial fibrillation (AF); or elevated NTproBNP ≥1500 pg\u002FmL or BNP ≥375 pg\u002FmL for patients with AF\n\nExclusion Criteria:\n\n* Current or planned long-term treatment with a mineralocorticoid receptor antagonist (MRA)\n* Documented prior history of severe hyperkalemia in the setting of MRA use\n* Estimated glomerular filtration rate (eGFR) \\\u003C25 mL\u002Fmin\u002F1.73m² or potassium \\>5.0 mmol\u002FL at screening\n* Acute myocardial infarction due to plaque rupture, coronary revascularization, valve replacement\u002Frepair, or implantation of a cardiac resynchronization therapy device within 30 days\n* Hemodynamically significant (severe) uncorrected primary cardiac valvular disease\n* Cardiomyopathy due to known acute inflammatory heart, infiltrative diseases, accumulation diseases, muscular dystrophies, cardiomyopathy with reversible causes, known hypertrophic obstructive cardiomyopathy, complex congenital heart disease, or known pericardial constriction\n* Probable alternative cause of participant's heart failure symptoms\n* Concomitant systemic therapy with potent cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitors or moderate CYP3A4 inducers, or potent CYP3A4 inducers\n* Known hypersensitivity to the IP (active substance or excipients)",{"count":232,"type":20},5200,[23],"Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.",[29,236],"Acute Heart Failure",[238,239,240,189],"Heart failure","Preserved ejection fraction","Mildly reduced ejection fraction","2026-07-02",{"date":243,"type":39},"2026-07-06",{"date":245,"type":39},"2024-01-17",{"date":247,"type":20},"2027-12",{"name":196,"class":46},315,{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":258,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":260,"conditions":261,"keywords":263,"overallStatus":267,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":277},"100637140","administering-atropine-through-autoinjectors-within-ambulance-services-for-poisoning-patients-in-sri-lankas-north-central-province-100637140","NCT07581301","Administering Atropine Through Autoinjectors Within Ambulance Services for Poisoning Patients in Sri Lanka's North Central Province","Feasibility of Using Ambulance Services to Administer Atropine Using Autoinjectors in Farming Communities in the North Central Province, Sri Lanka","FAST-AID","Inclusion Criteria:\n\n* Participants over the age of 18 who are willing and able to provide written informed consent will be asked to participate in the study.\n* Ambulance staff directly involved in the management and response to pesticide poisoning cases during the intervention period in the selected two geographical clusters.\n* Doctors and nurses from selected hospitals in the two geographical clusters who managed pesticide poisoning patients that received atropine via autoinjectors administered by ambulance staff during the intervention period.\n* Pesticide poisoning patients managed by Suwa Seriya ambulances in the selected two geographical clusters of the Anuradhapura district during the intervention period.\n\nExclusion Criteria:\n\n* Participants who are unwilling or unable to provide written informed consent will not be included in the study.\n* Participants who do not speak Sinhala.\n* Participants under the age of 18 years.",{"count":259,"type":20},30,"Pesticide poisoning remains one of the most serious public health challenges in rural Sri Lanka, particularly in the North Central Province (NCP), where intensive farming and heavy pesticide use have led to high rates of accidental and intentional poisoning. Although the antidote, atropine, is routinely used in hospitals, delays in receiving treatment often occur because patients must travel long distances before reaching care. Early initiation of treatment is critical, and survival depends on the speed with which atropine is administered.\n\nThe government's free 1990 Suwa Seriya ambulance service, established in 2016, provides emergency transport across Sri Lanka but currently has limited capacity for administering time-sensitive antidotes. Community consultations conducted during an earlier study revealed that people preferred life-saving treatments such as atropine to be managed through the formal health system, rather than stored in villages. This led to the idea of exploring whether ambulance staff could safely use atropine autoinjectors; simple, pre-filled devices that deliver the drug quickly and can safely be used even by non-medical professionals.\n\nThe FAST-AID study aims to assess the feasibility of introducing atropine autoinjectors into Sri Lanka's emergency ambulance system for use in pesticide poisoning cases. The main question is:\n\nHow feasible is it to integrate atropine autoinjectors into the ambulance service to provide earlier treatment for pesticide poisoning patients? Secondary questions explore (1) how ambulance coverage and travel routes affect timely administration; (2) how ambulance and hospital staff experience the use of the devices; and (3) how patients perceive the care they received.\n\nThe study will be carried out in the Anuradhapura District of the NCP, in collaboration with the Suwa Seriya ambulance service and selected hospitals. Two geographical clusters, one densely populated and one more remote, have been chosen to compare different service conditions. Around 30 pesticide poisoning patients will receive atropine using autoinjectors during ambulance transport, under guidance from an on-call emergency physician.\n\nData will be collected through several complementary methods:\n\n* Operational data from ambulance and hospital records (e.g., response times, use of autoinjectors, patient outcomes).\n* Geographic mapping (GIS) of ambulance coverage to assess accessibility and response patterns.\n* Focus group discussions with ambulance and hospital staff to explore training, practical challenges, and perceptions of the intervention.\n* Semi-structured interviews with patients to understand their lived experience of emergency care.\n* Participant observation in ambulances and hospitals to capture the everyday realities of emergency response.\n\nParticipants will be adults (aged 18 or above) who either work in the ambulance or hospital system or who have experienced pesticide poisoning and received atropine during the study period. All participants will provide written informed consent.\n\nThe research team will include Sri Lankan and UK collaborators from the University of Edinburgh and the South Asian Clinical Toxicology Research Collaboration (SACTRC).\n\nBy assessing the operational and social feasibility of using atropine autoinjectors in ambulances, this study aims to strengthen Sri Lanka's emergency response system and provide a foundation for a larger trial that could ultimately help save lives of those experiencing pesticide poisoning.",[262],"Pesticide Poisoning",[262,264,265,266],"Pre-Hospital Care","Atropine","Autoinjectors","NOT_YET_RECRUITING","2026-05-06",{"date":270,"type":39},"2026-05-12",{"date":272,"type":20},"2026-08-01",{"date":274,"type":20},"2027-02-01",{"name":276,"class":46},"University of Edinburgh",1,{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":282,"acronym":283,"eligibilityCriteria":284,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":285,"targetDuration":4,"studyType":21,"phases":287,"briefSummary":288,"conditions":289,"keywords":291,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":303},"100520593","phase-3-the-chronic-kidney-disease-adaptive-platform-trial-investigating-various-agents-for-therapeutic-effect-100520593","NCT06058585","The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect","CAPTIVATE","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Known chronic kidney disease from any cause (eGFR ≥25 mL\u002Fmin\u002F1.73m2)\n3. Currently receiving standard of care treatment according to treating physician\n4. Eligible for randomisation in at least one recruiting domain-specific appendix\n5. Participant and treating physician are willing and able to perform trial procedures\n\nExclusion Criteria:\n\n1. Planned to commence kidney replacement therapy or kidney transplant surgery in next 6 months\n2. Life expectancy less than 6 months",{"count":286,"type":20},1000,[23],"CAPTIVATE is an international, multi-centre, Phase III, adaptive, platform, randomised controlled trial in people with chronic kidney disease (CKD).\n\nCAPTIVATE aims to find the best treatment, or combination of treatments, that slow the progression of CKD so that fewer people develop kidney failure.\n\nCAPTIVATE provides a research platform that allows many treatment-related questions to be answered within a common trial set-up.",[290],"Chronic Kidney Diseases",[292,293,294],"Chronic kidney disease","Mineralocorticoid Receptor Antagonist","Finerenone","2026-03-26",{"date":72,"type":39},{"date":298,"type":39},"2024-09-04",{"date":300,"type":20},"2029-03-31",{"name":302,"class":46},"The George Institute",43,{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":310,"eligibilityCriteria":311,"healthyVolunteers":56,"sex":16,"minAge":312,"maxAge":313,"enrollmentInfo":314,"targetDuration":4,"studyType":21,"phases":316,"briefSummary":317,"conditions":318,"keywords":322,"overallStatus":267,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":329,"completionDateStruct":330,"leadSponsor":332,"locationsCount":277},"100626778","physical-inactivity-among-patients-with-cardiovascular-risk-100626778","NCT07440056","Physical Inactivity Among Patients With Cardiovascular Risk","Physical Inactivity Among Patients With Cardiovascular Risk: Proportion, Associated Factors, Perceived Barriers, and Effectiveness of an Intervention for Improvement at Government Primary Medical Care Institutions in Gampaha District","INSPIRE-PA","Inclusion Criteria:\n\n1. Patients permanently residing in Gampaha district for six months or more\n2. Patients registered and followed up at medical clinics in the same state sector PMCIs in Gampaha district, for a duration of three months or more\n\nExclusion Criteria:\n\n1. Pregnant mothers with any intermediate risk factor of chronic NCDs, followed up at state PMCIs in Gampaha district\n2. Patients diagnosed with atherosclerotic cardiovascular disease (ASCVD) (e.g. Coronary heart disease, Cerebrovascular disease, Peripheral artery disease, Aortic atherosclerotic disease) followed up at state sector primary medical care institutions in Gampaha district.\n3. Patients already diagnosed and on treatment for diabetes mellitus, any type of cancer and any chronic respiratory disease (e.g. Asthma, chronic obstructive pulmonary disease) followed up at state sector primary medical care institutions in Gampaha district, as their physical activity level and their knowledge on it may have changed following the diagnosis\n4. Patients with impaired cognitive functions (confirmed with medical records), as they are unable to report accurate responses independently.\n5. Patients who have undergone any surgical procedure within the last three months (confirmed by clinical documentation)\n6. Patients who have had any debilitating illness during the preceding week limiting their physical activity during the period of illness\n7. Patients who plan to change\u002Fchange their place of residence or shift their treatment follow-up from a state-sector PMCI to the private sector or any other treatment modality (e.g: Ayurveda) within the next six months","35 Years","65 Years",{"count":315,"type":20},192,[160],"The goal of this clinical trial is to learn if newly developed intervention package works to improve physical activity level among patients with intermediate cardiovascular risk factors. The main questions it aims to answer are:\n\nDoes the INSPIRE-PA intervention increase the level of physical activity among participants with intermediate cardiovascular risk factors?\n\n* What changes occur in physical activity level, BMI and blood pressure following participation in the intervention?\n* Are there any challenges, barriers, or unintended effects experienced by participants during the intervention period?\n* Researchers will compare the INSPIRE-PA intervention to usual care to determine whether the empowerment-based strategy is effective in improving physical activity levels and reducing cardiovascular risk among patients attending government primary medical care Iinstitutions.\n\nParticipants will:\n\n* Participate in the INSPIRE-PA program for 6 months\n* Attend scheduled follow-up visits at the primary medical care institution (e.g., every 2-4 weeks)for counselling, evaluation of physical activity level, and assessment of cardiovascular risk indicators\n* Engage in structured physical activity as recommended in the intervention package\n* Record their daily physical activity and any challenges or barriers in a physical activity logbook or diary\n* Undergo periodic measurements such as blood pressure, weight, waist circumference, and other relevant clinical assessments",[319,320,321],"Physical Activities","Cardiovascular (CV) Risk","Empowerment",[323,324,325,326],"Physical activity","primary care","behavioural intervention","level of physical activity improvement","2026-02-24",{"date":170,"type":39},{"date":72,"type":20},{"date":331,"type":20},"2026-09-30",{"name":333,"class":46},"University of Colombo",{"id":335,"slug":336,"hasResults":11,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":340,"eligibilityCriteria":341,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":342,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":344,"conditions":345,"keywords":348,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":361},"100626750","icu-related-out-of-pocket-expenses-icope-100626750","NCT07439692","ICU-related Out of Pocket Expenses (ICOPE)","ICU-related Out of Pocket Expenses (ICOPE) - A Multinational Prospective Study In African And Asian Countries.","ICOPE","Inclusion Criteria:\n\nAll patients admitted to the participating ICUs during a predefined window of 14 days and expected to have a duration of stay \\>24 hours will be eligible for the study.\n\nExclusion Criteria:\n\nlack informed consent.",{"count":343,"type":20},354,"The ICU-related Out-of-Pocket Expenses (ICOPE) study is a multinational, prospective observational study conducted in African and Asian countries to quantify ICU-related out-of-pocket expenditures and catastrophic health expenditure among patients and families. The study will include all patients admitted to participating ICUs during a predefined 14-day recruitment window, provided they have an ICU stay longer than 24 hours and informed consent is obtained. A minimum sample size of 354 patients is planned, including both ventilated and non-ventilated patients. Participants will be followed until ICU discharge, with additional follow-up at 30 days and 6 months after admission, resulting in a total study duration of 18 months. The primary objective is to quantify ICU-related out-of-pocket costs and assess the proportion of patients experiencing catastrophic health expenditure, comparing ventilated and non-ventilated groups, while secondary objectives include identifying risk factors for catastrophic expenditure and documenting coping strategies used by families to manage ICU costs.",[346,347],"Cost of ICU","Out of Pocket Expenses",[349,350,351,352],"OOPE","ICU-cost","LMIC","Critical Care","2026-02-23",{"date":170,"type":39},{"date":356,"type":39},"2024-12-01",{"date":358,"type":20},"2026-07-31",{"name":360,"class":46},"Nat Intensive Care Surveillance - MORU",44,{"id":363,"slug":364,"hasResults":11,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":368,"eligibilityCriteria":369,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":313,"enrollmentInfo":370,"targetDuration":4,"studyType":21,"phases":372,"briefSummary":374,"conditions":375,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":388},"100451881","phase-4-real-world-safety--efficacy-experience-of-empagliflozin-with-or-without-metformin-in-t2dm-patients---ease-study-100451881","NCT05164263","Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study","Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in Patients With Type II Diabetes Mellitus","EASE","Inclusion Criteria:\n\nPatient with T2DM between 18 to 65 years with HbA1C 7% - 10%, who can give informed consent. Patient uncontrolled on oral antidiabetics and lifestyle modification for at least 3 months. Patient who are empagliflozin naive. eGFR ˃60 mL\u002Fmin\u002F1.73m2.\n\nExclusion Criteria:\n\nType 1 diabetes, History of recurrent urinary tract infection (UTI), fungal infection, renal and\u002For hepatic dysfunctions, where RFT and Urine R\u002FE is abnormal, Diabetic Ketoacidosis and\u002For hyperosmolar hyperglycemic state, severe hypoglycemia, Pregnant or lactating women, Pancreatitis, any serious complications or hypersensitivity.",{"count":371,"type":20},2000,[373],"PHASE4","Study Objective To evaluate the safety and tolerability of Empagliflozin with or without metformin in patients with Type II Diabetes Mellitus in the Pakistani population.\n\nStudy design Open-label, prospective, observational, single arm, multi-center, post-marketing surveillance study.\n\nSample size The estimated sample size will be n=156. Duration of study 12 months (data lock point will be completion of 6 months' follow-up from the time of last patient's enrollment date) Safety Assessment: Patient will be monitored for Hypoglycemia, Dehydration, Hypotension, Urinary Tract Infections, Fungal Infections, Nausea, Vomiting, Diarrhea, Abdominal Discomfort, Flatulence, Asthenia, Indigestion and Other side effects (if any).\n\nFollow up visits: After recruitment, patient is supposed to have three visits for follow-ups.\n\nVisit 1: 4 to 6 weeks of initiation of therapy. Visit 02: At 12 weeks of initiation of therapy. Visit 03: At 24 weeks of initiation of therapy.\n\nLABORATORY TESTING:\n\nReputable Lab is considered for laboratory testing of diabetes patients i.e. HbA1C%, FBG, RFT and urine R\u002FE. The certified clinical lab will be responsible for receiving and analyzing clinical sample. Patients will have special discount of upto 50% for study related laboratory investigations.\n\nWhere in Urine Routine Examination (Urine R\u002FE), we consider as follows:\n\n* Visual Examination:\n\n  * Urine color: Normal (Yellow), Pale Yellow, Dark Yellow, Brown, Red or Pink or any other.\n  * Urine clarity: Clear, slightly Cloudy, cloudy or turbidity\n* Chemical Examination:\n\n  * Specific gravity\n  * pH\n  * Bilirubin\n  * Urobilinogen\n  * Protein\n  * Ketone\n  * Leukocyte Esterase\n* Microscopic Examination:\n\n  * Red Blood Cells:\n  * Epithelial Cells:\n  * Amorphous:\n  * Pus Cells\n  * Bacteria\n  * Yeast\n  * Casts\n  * Crystals\n\nWhere in Renal Function Test (RFT), we consider as follows:\n\n* Blood Urea Nitrogen (BUN): mg\u002FdL\n* Serum Creatinine: mg\u002FdL\n* Estimated Glomerular Filtration Rate (eGFR): mL\u002Fmin\u002F1.73 m2",[376,377,378],"Type II Diabetes Mellitus","Efficacy, Self","Safety Issues","2026-01-20",{"date":381,"type":39},"2026-01-22",{"date":383,"type":39},"2021-04-01",{"date":385,"type":20},"2027-08-31",{"name":387,"class":146},"Getz Pharma",6,{"id":390,"slug":391,"hasResults":11,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":11,"sex":396,"minAge":397,"maxAge":398,"enrollmentInfo":399,"targetDuration":4,"studyType":21,"phases":400,"briefSummary":401,"conditions":402,"keywords":408,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":277},"100598036","adipose-stem-cell-mitochondria-supplementation-to-oocytes-ascent-100598036","NCT07066267","Adipose Stem Cell Mitochondria Supplementation to Oocytes (ASCENT)","Clinical Application of Autologous Adipose Stem Mitochondria Transplantation to Oocytes for Improving Embryo Quality in Patients With Recurrent Pregnancy Failure","Inclusion Criteria:\n\n* Having at least three previous failed IVF trial\n* Specifically consented for to collect biopsies for Preimplantation generic testing for aneuploidy (PGTA) analysis\n* Specifically consented for to have single blastocyst transfer (recommended)\n* No major uterine or ovarian abnormalities\n* Specifically consented for to have all embryos frozen\n* Specifically consented for to collect adipose tissues from subcutaneous liposuction\n* BMI level level \\\u003C26kg\u002Fm2\n\nExclusion Criteria:\n\n* Ovarian endometriosis with Chocolate cysts (American Fertility Society (AFS)) classification type 3 and 4\n* Any medical contraindication oocyte retrieval or subsequent procedures Ovarian hyperstimulation syndrome Bleeding disorders Sex hormone allergies Severe emotional defect on injections\n* Severe sperm abnormalities\n* \\\u003C5 million\u002FmL motile sperm\n* Uterine structural anomalies\n* Polycystic ovaries\n* Premature ovarian failure","FEMALE","29 Years","39 Years",{"count":5,"type":20},[160],"The purpose of this study is to investigate the potential of autologous adipose stem cell (ASC) mitochondrial transfer (ASCENT) to oocytes along with intracytoplasmic sperm injection (ICSI)as a means of enhancing embryo development and improving the success rate of in patients with a history of multiple IVF failures. Embryo quality plays a crucial role in determining the success of assisted reproductive technologies and directly contributes to repeated pregnancy failures. Several factors, including age, physiological conditions, genetics, and environmental influences, can significantly impact embryo quality. Oocytes, the largest cells in the human body, are heavily reliant on mitochondria. Mitochondria's role in providing energy for oocytes is crucial, and insufficient energy production has been linked to poor oocyte and embryo quality. Some human studies have shown that increasing oocyte mitochondrial mass can improve embryo quality in patients who have experienced repeated IVF failures.",[403,404,405,406,407],"Female Infertility","Oocyte Competence","Mitochondria","Recurent Implantation Failures","Advanced Age",[409,410,411,412,413],"mitochondria","mitochondria transplantation","Adipose stem cell","oocyte","Female infertility","2025-07-14",{"date":416,"type":39},"2025-07-17",{"date":418,"type":39},"2025-04-25",{"date":420,"type":20},"2026-12-31",{"name":422,"class":146},"Sunkaky Medical Cooperation",{"id":424,"slug":425,"hasResults":11,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":430,"enrollmentInfo":431,"targetDuration":4,"studyType":21,"phases":433,"briefSummary":434,"conditions":435,"keywords":437,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":277},"100576101","comparing-efficacy-of-dry-needling-combined-with-passive-stretching-and-muscle-energy-technique-on-myofascial-trigger-points-100576101","NCT06780904","Comparing Efficacy of Dry Needling Combined with Passive Stretching and Muscle Energy Technique on Myofascial Trigger Points","Comparing the Efficacy of Dry Needling Combined with Passive Stretching and Muscle Energy Technique on Upper Trapezius Myofascial Trigger Points Associated with Neck Pain","Inclusion Criteria:\n\n* Presence of neck pain for at least 3 months or more\n* Presence of trigger points in the upper trapezius muscle, either unilaterally or bilaterally\n* Age between 18 and 60 years\n\nExclusion Criteria:\n\n* Having an ongoing infection or fever\n* Presence of shoulder pathology, such as tendinopathy, impingement syndrome, capsulitis, or bursitis\n* History of direct trauma to the shoulder or neck\n* Immunosuppressed individuals (e.g., those with cancer)\n* Pregnant or recently delivered\n* Diagnosis of fibromyalgia\n* History of previous neck or shoulder surgery\n* Previous local steroid injection or acupuncture\n* Any abnormality that restricts cervical range of motion (e.g., degenerative changes, cervical spine spondylolisthesis, disc protrusion, extrusion, or sequestration observed in MRI)\n* Uncontrolled diabetes mellitus\n* Needle phobia\n* Metal allergies\n* Cervical instability\n* Presence of local skin lesions or infections\n* Significant cognitive impairment or uncooperative behavior\n* Participants who have previously undergone any form of physiotherapy intervention for the treatment of neck pain or related conditions","60 Years",{"count":432,"type":20},46,[160],"The goal of this clinical trial is to assess and compare the efficacy of dry needling (minimally invasive treatment by using a tiny needle) combined with two types of stretching techniques in patients with neck pain for more than 3 months. The main questions it aims to answer are:\n\nWhich combination of treatment will 1.give faster relief of pain? 2.improve neck range of motion? and 3.improve disability level of a person with neck pain.\n\nParticipants who are interested will be selected according to eligibility criteria. Participants will be divided into two groups. Initially researcher will assess and interview the participants. Two groups will receive two different combinations of interventions. Pre and post measurements will be obtained and then treatment efficacy will be assessed.",[436],"Neck Pain",[438,439,440,441,442,443],"myofascial trigger points","passive stretching","dry needling","Muscle Energy Technique (MET)","Randomized clinical trial","Upper trapezius","2025-01-15",{"date":446,"type":39},"2025-01-17",{"date":448,"type":39},"2024-09-01",{"date":450,"type":20},"2025-03-01",{"name":452,"class":46},"University of Peradeniya",{"id":454,"slug":455,"hasResults":11,"nctId":456,"briefTitle":457,"officialTitle":457,"acronym":458,"eligibilityCriteria":459,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":460,"targetDuration":4,"studyType":21,"phases":462,"briefSummary":463,"conditions":464,"keywords":466,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":479},"100465792","phase-3-sglt2-inhibitors-as-first-line-therapy-to-prevent-renal-decline-in-type-2-diabetes-100465792","NCT05345327","SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes","START","Inclusion Criteria:\n\n* Diagnosis of T2D;\n* Aged ≥18 years;\n* Body mass index \\> 18.5 kg\u002Fm2;\n* Drug naïve, or managed with metformin monotherapy and willing to be randomised to either dapagliflozin or metformin;\n* eGFR ≥45 ml\u002Fmin\u002F1,73m2; and\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Have an immediate need for rapid intensification of glucose lowering therapy due to marked hyperglycaemia; or\n* There is a definite indication for, or contraindication to, either metformin or SGLT2 inhibitor; or\n* They have clearly documented coronary artery disease (defined as a previous acute coronary syndrome, coronary stent or bypass surgery) or clearly documented heart failure (defined on the basis of a hospital admission, specialist diagnosis or an echocardiogram or other imaging modality); or\n* Pregnant or breast-feeding.",{"count":461,"type":20},994,[23],"The aim of the trial is to evaluate the effects of the SGLT2 inhibitor, dapagliflozin, compared to metformin on annual decline in eGFR when used as first line therapy in people with Type 2 Diabetes.",[465],"Type 2 Diabetes",[467,468,469,470],"Diabetes","Renal decline","Metformin","Sodium Glucose Co-Transporter 2 inhibitor","2024-12-17",{"date":473,"type":39},"2024-12-20",{"date":475,"type":39},"2023-01-01",{"date":477,"type":20},"2026-06-30",{"name":302,"class":46},8,{"id":481,"slug":482,"hasResults":11,"nctId":483,"briefTitle":484,"officialTitle":484,"acronym":485,"eligibilityCriteria":486,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":487,"targetDuration":489,"studyType":59,"phases":4,"briefSummary":490,"conditions":491,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":5},"100296434","validation-of-the-lupus-low-disease-activity-state-lldas-in-the-asia-pacific-region-100296434","NCT03138941","Validation of the Lupus Low Disease Activity State (LLDAS) in the Asia Pacific Region","APLCLLDAS","Inclusion Criteria:\n\n* All patients have to meet either the 1997 American College of Rheumatology (ACR) Modified Classification Criteria for SLE, with at least four of the 11 items; or alternatively, fulfil the Systemic Lupus International Collaborating Clinics (SLICC) 2012 Classification Criteria, with at least four of the 17 items (at least one clinical and one immunological criterion) or with lupus nephritis in the presence of at least one immunological criteria. Patients can be either newly diagnosed or longstanding lupus patients.\n\nAll patients must be over the age of 18 and competent to provide written consent.\n\nExclusion Criteria:\n\n* Patients less than 18 years of age and patients who are unable to consent are excluded from the study.",{"count":488,"type":20},5000,"10 Years","Lupus Low Disease Activity State (LLDAS) study is an international, multi-centre prospective study, developed by the Asia Pacific Lupus Collaboration (APLC) to investigate whether the attainment of LLDAS is associated with improved outcomes in patients with Systemic Lupus Erythematosus (SLE).\n\nSLE, or lupus, is the archetypal multisystem autoimmune disease, with an estimated incidence of 5-50 cases per 100,000 people. Patients with SLE, usually young women, suffer a marked loss of life expectancy, and severe morbidity, due to a heterogeneous range of clinical manifestations caused by autoimmune-mediated inflammation of multiple organs. The most severe manifestations of SLE are the accrual of irreversible organ damage, especially renal and central nervous system (CNS) involvement. As there is no effective targeted monotherapy for SLE, patients also suffer severe toxicity from the use of glucocorticoids and broad-spectrum immunosuppressive therapies. Despite combination therapy with current drugs, many studies show that the majority of patients suffer inadequate disease control and inexorably accrue permanent organ damage over time.\n\nThe diversity of clinical features of active SLE has made quantification of disease activity problematic. Although there are a number of published systems in use to measure SLE disease activity, there are widely acknowledged problems with these instruments. Published definitions of remission are so stringent that they are met by less than 5% of patients. This lead to the realisation that rather than lupus remission, a lupus low disease activity state target may be more feasible, and that patients with low disease activity are more homogeneous than patients with active disease. Thus, the development of a definition of lupus low disease activity, which is feasible and has face validity, escapes the complexity of attempts to quantify heterogeneous states of active disease.\n\nIn this study, the investigators will prospectively collect longitudinal data on consecutive SLE patients at each centre to evaluate the LLDAS definition. Protection from organ damage accrual as the primary endpoint.",[492],"Systemic Lupus Erythematosus","2024-12-09",{"date":495,"type":39},"2024-12-12",{"date":497,"type":39},"2013-09-01",{"date":499,"type":20},"2032-12-31",{"name":501,"class":46},"Monash University",{"id":503,"slug":504,"hasResults":11,"nctId":505,"briefTitle":506,"officialTitle":507,"acronym":4,"eligibilityCriteria":508,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":398,"enrollmentInfo":509,"targetDuration":4,"studyType":21,"phases":511,"briefSummary":512,"conditions":513,"keywords":519,"overallStatus":267,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":537},"100570792","testing-and-comparing-the-impacts-of-mhealth-based-and-web-based-education-on-oral-cancer-100570792","NCT06711848","Testing and Comparing the Impacts of Mhealth-Based and Web-Based Education on Oral Cancer","A Comparative Analysis of the Effectiveness, Usability, Uptake, and Acceptability of an Educational Website and a Mobile Health Application Prototype in Improving Knowledge on Oral Cancer","Inclusion Criteria:\n\n* being a first-year bachelor degree student of either University of Rwanda (Rwanda), University of Peradeniya (Sri Lanka), Usmanu Danfodiyo University (Nigeria), University of Ibadan (Nigeria), or Saveetha University (India)\n* being within the age range of 18 to 39 years\n* having a personal smartphone\n* willingness to participate in the study\n\nExclusion Criteria:\n\n* being a member of staff or a visitor or a non-first year bachelor degree student of University of Rwanda (Rwanda), University of Peradeniya (Sri Lanka), Usmanu Danfodiyo University (Nigeria), University of Ibadan (Nigeria), or Saveetha University (India)\n* being a student of a tertiary institution not selected for the study\n* being below the age of 18 years or above the age of 39 years.\n* not having a personal smartphone\n* not willing to participate in the study",{"count":510,"type":20},75,[160],"Introduction: Oral cancer is a malignant neoplastic disease affecting the lip, oral cavity (mouth) and\u002For the oropharynx. Despite the intense and diverse public health interventions on oral cancer prevention, the global prevalence rates of oral cancer and its major risk factors are still very high. Hence, oral cancer is an issue of serious global health importance.\n\nAim: To test and compare the effectiveness, usability, uptake, and acceptability of an educational website and a mobile health application prototype on oral cancer in improving oral cancer knowledge among university students.\n\nMethods: This study will adopt a randomised control trial design, and it will be conducted among 75 first-year bachelor's degree students from five universities across two continents: University of Rwanda (Rwanda, Africa), Usmanu Danfodiyo University (Nigeria, Africa), University of Peradeniya (Sri Lanka, Asia), University of Ibadan (Nigeria), and Saveetha University (India, Aisa). The study participants will be in three groups (Group 1, Group 2, and Group 3). The participants in Group 1 will be the control group (n = 25 participants; 5 participants from each university); that is the group that will not receive an educational intervention. However, those in Group 2 (n = 25 participants; 5 participants from each university) will receive a web-based educational intervention on oral cancer while those in Group 3 (n = 25 participants; 5 participants from each university) will receive an app-based educational intervention on oral cancer. Pretest survey and posttest survey will be done for all participants. The data collected will be statistically analysed using the Statistical Package for Social Sciences (SPSS) version 28 software. Descriptive statistics will be done for all variables while inferential statistics (analysis of variance) will be done to test for associations between variables of interest.\n\nConclusion: The findings of this study will determine the effectiveness, usability, uptake, and acceptability of the tested digital intervention tools.",[514,515,516,517,518],"Oral Cancer","Health Education, Community","Digital Intervention","MHealth Application","MHealth Intervention",[520,521,522,523,524,525,526,527],"mobile health","application","website","impact","knowledge","oral cancer","public health","intervention","2024-11-28",{"date":530,"type":39},"2024-12-02",{"date":532,"type":20},"2025-01-05",{"date":534,"type":20},"2025-04-30",{"name":536,"class":46},"University of Rwanda",5,{"id":539,"slug":540,"hasResults":11,"nctId":541,"briefTitle":542,"officialTitle":543,"acronym":4,"eligibilityCriteria":544,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":545,"targetDuration":4,"studyType":21,"phases":547,"briefSummary":548,"conditions":549,"keywords":552,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":557,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":563,"locationsCount":277},"100551195","a-pilot-study-comparing-the-efficacy-of-traditional-buddhist-mindfulness-training-versus-secular-mindfulness-based-cognitive-therapy-for-patients-having-residual-depressive-symptoms-100551195","NCT06456931","A Pilot Study Comparing the Efficacy of Traditional Buddhist Mindfulness Training Versus Secular Mindfulness-based Cognitive Therapy for Patients Having Residual Depressive Symptoms","Comparing the Efficacy of Traditional Buddhist Mindfulness Training Versus Secular Mindfulness-based Cognitive Therapy for Residual Depressive Symptoms in Patients With Depressive Disorders: a Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 18 or above\n* Buddhist faith (Only Buddhists are selected as one of the interventions involves Buddhist teachings, and any recruited participant has a probability of being enrolled in the Buddhist mindfulness intervention)\n* A history of one or more episodes of moderate or severe depression\n* Currently having BDI-II score \\> 13, i.e., mild to moderate depressive symptoms\n\nExclusion Criteria:\n\n* Currently having a severe depressive episode, according to the Composite International Diagnostic Interview (CIDI) Sinhalese version\n* Currently having moderate to severe suicidal ideation (according to CIDI)\n* Recent changes in antidepressant medication\n* Unable to understand and communicate in Sinhalese",{"count":546,"type":20},60,[160],"This interventional study is conducted with the goal of comparing the efficacy of traditional Buddhist mindfulness training versus secular mindfulness based cognitive therapy among patients with depressive disorders. We are also interested in studying how these interventions compare in terms of preventing further relapses of depression. Additionally, this study aims to identify factors that influence the efficacy of this intervention, such as self-report mindfulness, self-compassion, and religiosity.",[550,551],"Depression Moderate","Depression Mild",[553,554,555],"mindfulness","depression","religiosity","2024-06-07",{"date":558,"type":39},"2024-06-13",{"date":560,"type":39},"2024-04-01",{"date":562,"type":20},"2025-10-31",{"name":564,"class":46},"Anuradha Baminiwatta",{"id":566,"slug":567,"hasResults":11,"nctId":568,"briefTitle":569,"officialTitle":570,"acronym":571,"eligibilityCriteria":572,"healthyVolunteers":11,"sex":16,"minAge":573,"maxAge":574,"enrollmentInfo":575,"targetDuration":4,"studyType":21,"phases":577,"briefSummary":578,"conditions":579,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":47},"100469621","phase-3-erythropoietin-for-neonatal-encephalopathy-in-lmic-embrace-trial-100469621","NCT05395195","Erythropoietin for Neonatal Encephalopathy in LMIC (EMBRACE Trial)","Erythropoietin Monotherapy for Brain Regeneration in Neonatal Encephalopathy in Low and Middle-Income Countries","EMBRACE","Inclusion Criteria (all of below should be met)\n\n* Inborn babies born at a gestational age greater than or equal to 36 weeks, with a birth weight \\>=1.8 kg\n* At least one of the following: need for continued resuscitation at 5 minutes of age; 5-minute Apgar score \\\u003C 6; metabolic acidosis (pH \\\u003C 7.0; base deficit \\> 16 mmol\u002FL) in cord or blood gas within the first hour of birth.\n* Moderate or severe neonatal encephalopathy on modified Sarnat staging performed between 1 to 6 hours after birth.\n\nExclusion Criteria:\n\n* Imminent death at the time of recruitment\n* Babies born at home or those admitted after 6 hours of birth.\n* Major life-threatening congenital malformations\n* Head circumference \\\u003C30 cm at birth\n* Babies undergoing induced hypothermia\n* Migrant family or parents unable\u002Funlikely to come back for follow-up at 18 months\n* Sentinel event and encephalopathy occurred only after birth\n* Unable to consent in primary language of parent(s)","1 Hour","6 Hours",{"count":576,"type":20},504,[23],"One million babies die, and at least 2 million survive with lifelong disabilities following neonatal encephalopathy (NE) in low and middle-income countries (LMICs), every year. Cooling therapy in the context of modern tertiary intensive care improves outcome after NE in high-income countries. However, the uptake and applicability of cooling therapy in LMICs is poor, due to the lack of intensive care and transport facilities to initiate and administer the treatment within the six-hours window after birth as well as the absence of safety and efficacy data on hypothermia for moderate or severe NE.\n\nErythropoietin (Epo) is a promising neuroprotectant with both acute effects (anti-inflammatory, anti-excitotoxic, antioxidant, and antiapoptotic) and regenerative effects (neurogenesis, angiogenesis, and oligodendrogenesis),which are essential for the repair of injury and normal neurodevelopment when used as a mono therapy in pre-clinical models (i.e without adjunct hypothermia).\n\nThe preclinical data on combined use of Eythropoeitin and hypothermia is less convincing as the mechanisms overlap. Thus, the HEAL (High dose erythropoietin for asphyxia and encephalopathy) trial, a large phase III clinical trial involving 500 babies with with encephalopathy reported that that Erythropoietin along with hypothermia is not beneficial.\n\nIn contrast, the pooled data from 5 small randomized clinical trials (RCTs) (n=348 babies), suggests that Epo (without cooling therapy) reduce the risk of death or disability at 3 months or more after NE (Risk Ratio 0.62 (95% CI 0.40 to 0.98). Hence, a definitive trial (phase III) for rigorous evaluation of the safety and efficacy of Epo monotherapy in LMIC is now warranted.",[580,581,582],"Encephalopathy","Erythropoietin","Newborn Asphyxia","2024-03-18",{"date":585,"type":39},"2024-03-19",{"date":587,"type":39},"2022-12-31",{"date":589,"type":20},"2026-12-01",{"name":76,"class":46},""]